NMS · Financial Statements

Upstream Bio, Inc. (UPB) Revenue, Earnings & Financial Statements

$2.10 NMS: UPB Market Cap $115.10M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Upstream Bio, Inc. most recently reported annual revenue of $3.0M, a net loss of $143.0M. Revenue grew at an average annual rate of 44.2% over the last 3 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Upstream Bio, Inc.: Revenue rose from $1.0M in 2022 to $3.0M in 2025, a change of +200.0% over 3 years; net profit was positive in 0 of 4 reported years; operating margin moved from -1972.7% to -5618.8%, a shift of -3646.1 percentage points; the most recent year shows a net loss of $143.0M.

Income Statement — 4 Years (USD millions)

Metric2022202320242025
Revenue$1.0M$2.0M$2.0M$3.0M
Operating Expenses$25.0M$42.0M$80.0M$163.0M
Operating Profit−$24.0M−$40.0M−$78.0M−$160.0M
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Other Income$0$20.0M$15.0M$17.0M
Interest$0$0$0$0
Depreciation$0$0$0$0
Profit Before Tax−$24.0M−$21.0M−$63.0M−$143.0M
Tax rate (%)0.0%0.0%0.0%0.0%
Net Profit−$24.0M−$21.0M−$63.0M−$143.0M
EPS−$0.66−$1.05−$1.49−$2.66

Quarterly Results — Last 12 Quarters (USD millions)

1 duplicate period label in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$0
Operating Expenses$15.0M$16.0M$18.0M$20.0M$27.0M$33.0M$45.0M$39.0M$47.0M$45.0M$43.0M$44.0M
Operating Profit−$14.0M−$15.0M−$18.0M−$19.0M−$26.0M−$32.0M−$44.0M−$38.0M−$46.0M−$44.0M−$42.0M−$43.0M
Operating Margin-3184.4%-2345.8%-3439.2%-3112.5%-4293.3%-5656.0%-4732.9%-5539.4%-6911.2%-4218.1%-5481.0%-10982.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$12.0M−$11.0M−$15.0M−$16.0M−$21.0M−$27.0M−$40.0M−$34.0M−$42.0M−$41.0M−$40.0M−$41.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$12.0M−$11.0M−$15.0M−$16.0M−$21.0M−$27.0M−$40.0M−$34.0M−$42.0M−$41.0M−$40.0M−$41.0M
EPS−$0.41−$0.27−$0.38−$0.41−$0.41−$0.51−$0.74−$0.63−$0.79−$0.75−$0.73−$0.75

Over the 4 years reported for Upstream Bio, Inc., cash stood at $102.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 27.08 times.

Balance Sheet — 4 Years (USD millions)

Metric2022202320242025
Total Assets$18.0M$117.0M$482.0M$354.0M
Current Assets$18.0M$117.0M$479.0M$352.0M
Cash$17.0M$26.0M$326.0M$102.0M
Inventory$0$0$0$0
Receivables$0$0$1.0M$1.0M
Fixed Assets$0$0$2.0M$2.0M
Capital Work in Progress$0$0$0$0
Investments$0$84.0M$145.0M$240.0M
Other Assets$0$0$0$0
Total Liabilities$125.0M$240.0M$12.0M$14.0M
Current Liabilities$5.0M$7.0M$11.0M$13.0M
Borrowings$0$0$2.0M$1.0M
Other Liabilities$125.0M$240.0M$10.0M$13.0M
Equity$0$0$0$0
Reserves−$106.0M−$123.0M$470.0M$340.0M

For Upstream Bio, Inc., operating cash flow was positive in 0 of 4 reported years; free cash flow in the latest year was negative at $133.0M; free cash flow was positive in 0 of 4 years.

Cash Flow Statement — 4 Years (USD millions)

Metric2022202320242025
Operating Cash Flow−$19.0M−$38.0M−$59.0M−$133.0M
Investing Cash Flow$0−$83.0M−$60.0M−$94.0M
Financing Cash Flow$0$0−$4.0M$0
Net Cash Flow−$9.0M$9.0M$300.0M−$224.0M
Free Cash Flow−$19.0M−$38.0M−$60.0M−$133.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA-0.67
FCF Yield-74.31%
Quick Ratio27.99
Interest Coverage—
Return 1Y-88.09%
Return 3Y—
Return 5Y—

Upstream Bio, Inc. (UPB) financials — frequently asked questions

What is Upstream Bio, Inc.'s annual revenue?

Upstream Bio, Inc. (UPB) reported annual revenue of $3.0M in its most recent fiscal year.

What is Upstream Bio, Inc.'s net profit?

Upstream Bio, Inc. (UPB) reported a net loss of $143.0M in its most recent fiscal year.

What is UPB EV/EBITDA?

Upstream Bio, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.67. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
UPB Overview UPB Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.